clinical trial · NCT05962398
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
CSL Behring·—·enrolling by invitation·n = 56
Hemophilia BAAV5-hFIXco-Padua
brief summary
The primary purpose of this study is to assess the long-term safety and efficacy in male adults with hemophilia B who were treated with CSL222 (CSL222) in parent studies CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).
started
Aug 30, 2023
primary completion
Mar 23, 2035
completion
Mar 23, 2035
last updated
Jul 18, 2025
official title
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol